[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 714
Citations 0
Comment & Response
November 22/29, 2016

Cost-effectiveness of PCSK9 Inhibitor Therapy

Author Affiliations
  • 1Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Tarrytown, New York
  • 2Global Health Economics and Outcomes Research, Sanofi, Bridgewater, New Jersey
JAMA. 2016;316(20):2151-2152. doi:10.1001/jama.2016.16286

To the Editor Cardiovascular disease (CVD) remains the leading cause of death in the United States. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an important treatment option for patients at highest risk of CVD who are unable to reach their lipid goals with current treatments. Dr Kazi and colleagues1 suggested that use of PCSK9 inhibitors for patients with atherosclerotic CVD and heterozygous familial hypercholesterolemia is not cost-effective and that these medicines will increase costs to the US health care system. These findings depend on questionable assumptions that overestimate the calculated cost-effectiveness ratio and thus underestimate the value of PCSK9 inhibitors.

First Page Preview View Large
First page PDF preview
First page PDF preview
×